KZIA - Kazia Therapeutics Limited

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.6900
+0.0400 (+1.51%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.6500
Open2.8400
Bid2.6700 x 1000
Ask6.0200 x 1100
Day's Range2.6240 - 2.8400
52 Week Range2.2400 - 9.7400
Volume3,627
Avg. Volume17,947
Market Cap19.761M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.9200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?
      Simply Wall St.

      Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?

      James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...

    • ACCESSWIRE

      Edison issues ADR update on Kazia Therapeutics (KZIA)

      LONDON, UK / ACCESSWIRE / January 13, 2020 / Kazia Therapeutics (NASDAQ:KZIA) has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE ...

    • Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
      PR Newswire

      Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

      Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase II / III study in glioblastoma. It is expected that data from GBM AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory agencies.

    • ACCESSWIRE

      Edison issues ADR outlook on Kazia Therapeutics (KZIA)

      LONDON, UK / ACCESSWIRE / December 2, 2019 / Kazia Therapeutics (NASDAQ:KZIA) has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data are ...

    • If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
      Simply Wall St.

      If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%

      The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

    • Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
      PR Newswire

      Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

      Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. This data is the subject of a poster presentation at the annual meeting of the Society for Neuro-Oncology (SNO), held in Phoenix, AZ from 20 - 24 November 2019.

    • Kazia Raises A$4.0 Million to Progress R&D Programs
      PR Newswire

      Kazia Raises A$4.0 Million to Progress R&D Programs

      NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, professional, and sophisticated investors in Australia and internationally, at a price of A$0.40 per New Share (Institutional Placement). The Institutional Placement will raise A$4.0 million (exclusive of costs).

    • Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
      PR Newswire

      Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

      SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and were presented by New Zealand Prime Minister Jacinda Arden at a ceremony in Auckland on September 12. Kazia was recognised for being an innovative, product-focused and agile company and the award also reflected its significant progress in the clinical testing of its lead candidate, GDC-0084, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults, as well as other forms of brain cancer.

    • St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
      PR Newswire

      St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

      NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's investigational new drug, GDC-0084 in diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas, which represent a group of childhood brain cancers with high unmet need. Dr. Christopher Tinkle, co-Lead Investigator on the study, commented, "to date, thirteen patients have received GDC-0084 in our study.

    • Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
      PR Newswire

      Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

      NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain (brain metastases and leptomeningeal metastases). This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.

    • Kazia calls for greater awareness of the deadliest brain cancer in the US
      PR Newswire

      Kazia calls for greater awareness of the deadliest brain cancer in the US

      SYDNEY , July 17, 2019 /PRNewswire/ --  T his Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the ...

    • How Kazia Therapeutics Limited (ASX:KZA) Can Impact Your Portfolio Volatility
      Simply Wall St.

      How Kazia Therapeutics Limited (ASX:KZA) Can Impact Your Portfolio Volatility

      If you're interested in Kazia Therapeutics Limited (ASX:KZA), then you might want to consider its beta (a measure of...

    • Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
      PR Newswire

      Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology

      NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute. Alliance will launch a multi-centre phase II study to investigate the potential use of Kazia's investigational new drug, GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases (cancer that has spread to the brain).

    • New positive data from phase IIa trial in brain cancer patients
      PR Newswire

      New positive data from phase IIa trial in brain cancer patients

      NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce new safety data from its ongoing phase IIa study of GDC-0084 in newly-diagnosed patients with glioblastoma (GBM). Licensed from Genentech in October 2016, GDC-0084 is a novel targeted therapy that inhibits the PI3K pathway, which is important in many forms of cancer and is activated in 85-90% of GBM cases. The phase II a study has determined a maximum tolerated dose (MTD) of 60mg, which is substantially higher than the 45mg dose found during Genentech's phase I study in patients with recurrent disease.

    • Kazia calls for greater awareness of the deadliest gynecological cancer in the US
      PR Newswire

      Kazia calls for greater awareness of the deadliest gynecological cancer in the US

      SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal gynaecological cancer in the US. In 2019, around 22,530 women will receive a new diagnosis of ovarian cancer[1] while the disease has one of the lowest survival rates of all female cancers, with only 46.5% of patients surviving five years post diagnosis[2]. Kazia's CEO, Dr James Garner said, "In 2019, more than 13,000 women will die from ovarian cancer in the US, so we are urging all women to understand all of the major signs and symptoms of ovarian cancer and seek regular check-ups with their doctors if feeling unwell.

    • PR Newswire

      Kazia calls for greater awareness of the most lethal women's disease in Australia

      SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are diagnosed with ovarian cancer[1], most of them at an advanced stage. Kazia's CEO, Dr James Garner said, "Every eight hours in Australia a woman will die from ovarian cancer, so we are urging all women to understand all of the major signs and symptoms of ovarian cancer and seek regular check-ups with their doctors if feeling unwell.

    • Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
      Simply Wall St.

      Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

      If you want to know who really controls Kazia Therapeutics Limited (ASX:KZA), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders ownin...